Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review
Pfizer will no longer invest in the development of its oral GLP-1 drug danuglipron after the pharma detected a potential...
Pfizer will no longer invest in the development of its oral GLP-1 drug danuglipron after the pharma detected a potential...